Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors
Approximately 800,000 strokes occur each year in the United States alone. A majority of people survive, due in part to key advances in patient care over the years, but they often go forward without receiving the long-term help they need to recover and thrive.
Advancing AI for vascular surgery will require a commitment to data integrity
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
Industry concerns over paclitaxel-coated devices may have put PAD patients at risk
Back in 2019, the FDA issued a warning about the use of paclitaxel-coated devices when treating peripheral artery disease. The agency took back that warning in 2023, but it appears to have made a significant impact on patient care.
Genetic predisposition to depression increases CVD risk in women, but not men
The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.
Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups
As more high-risk patients undergo PCI, what is the best antiplatelet strategy following an initial event-free period of DAPT? Does it change after complex PCI? Researchers aimed to answer these questions, and many others, with new findings published in JAMA Cardiology.

Dabigatran no more effective than aspirin for recurrent stroke prevention

The popular anticoagulant dabigatran is no more effective than aspirin when it comes to preventing recurrent stroke in patients with a history of embolic events, researchers reported in the New England Journal of Medicine May 16.

May 21, 2019

T-cells in arterial plaque could signal stroke risk

Researchers have linked a specific type of immune cell found in arterial plaque to increased probability of a stroke or mini-stroke.

May 17, 2019

FDA approves 1st anticoagulant for use in pediatric patients

Fragmin (dalteparin sodium), a type of heparin that works as an anticoagulant, was approved by the FDA May 16 to treat symptomatic venous thromboembolism (VTE) in pediatric patients aged one month and up.

May 17, 2019

Arthritic pain reliever glucosamine cuts risk of CVD death by 22%

A dietary supplement commonly used to relieve osteoarthritis and joint pain may also double as a cardioprotector, Tulane University researchers reported in The BMJ May 14.

May 16, 2019

Bioengineered blood vessels could replace vasculature damaged by renal failure, CVD

A team funded by the National Institutes of Health has succeeded in growing human acellular vessels—implantable, bioengineered human blood vessels—to replace damaged vasculature in patients with end-stage kidney failure.

May 10, 2019

Migraine drug shows no increase in CV outcomes

The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.

May 6, 2019

Virtue sirolimus-eluting balloon granted breakthrough designation for coronary ISR

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

April 24, 2019

FDA schedules June meeting to discuss safety of paclitaxel devices

The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in mid-June to discuss recent controversies and safety practices surrounding paclitaxel-coated and -eluting medical devices, according to a notice posted April 22.

April 24, 2019

Vascular & Endovascular

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors

Advancing AI for vascular surgery will require a commitment to data integrity

Industry concerns over paclitaxel-coated devices may have put PAD patients at risk

Genetic predisposition to depression increases CVD risk in women, but not men

Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups